Brentuximab vedotin for the treatment of patients with hodgkin lymphoma Journal Article
| Author: | Younes, A. |
| Article Title: | Brentuximab vedotin for the treatment of patients with hodgkin lymphoma |
| Abstract: | Hodgkin lymphoma (HL) is a relatively rare but highly curable human cancer. Because very few patients relapse and will require subsequent therapy, new drug development for HL has not been seen as a high priority by the pharmaceutical industry. Brentuximab vedotin, an antibody-drug conjugate that targets CD30 receptors, became the first drug to be approved by regulatory agencies for the treatment of HL in more than 30years. This review summarizes the current and future directions of incorporating brentuximab vedotin in the management of patients with HL. © 2014 Elsevier Inc. |
| Keywords: | cancer chemotherapy; unclassified drug; allogeneic stem cell transplantation; clinical trial; drug tolerability; fatigue; review; doxorubicin; placebo; drug withdrawal; gemcitabine; drug megadose; antineoplastic agent; multiple cycle treatment; nausea; neuropathy; peripheral neuropathy; hodgkin disease; monoclonal antibody; drug dose escalation; bleomycin; navelbine; drug substitution; classical hodgkin lymphoma; sgn 30; antibody-drug conjugate; brentuximab vedotin; reed-sternberg; cd30; human; priority journal; iratumumab; xmab 2513 |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 28 |
| Issue: | 1 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-02-01 |
| Start Page: | 27 |
| End Page: | 32 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2013.10.005 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 2 January 2014 -- CODEN: HCNAE -- Source: Scopus |
